Daniel Schneider - Photocure ASA President CEO
| PHCUF Stock | USD 5.60 1.12 25.00% |
CEO
Mr. Daniel Schneider was appointed President and Chief Executive Officer of PHOTOCURE ASA effective as of prior to November 1, 2018. Mr. Schneider holds an MBA from Washington University and a BS degree in Business Administration from St. Louis University with a double major in Finance and Marketing. Mr. Schneider has commercial experience from the U.S. healthcare industry, including his previous position as General Manager for Ablynx N.V. in North America. Mr. Schneider has also held executive management positions in other pharmaceutical and biotech companies, including BTG International, Somaxon Pharmaceuticals and Sepracor. since 2018.
| Tenure | 6 years |
| Phone | 47 22 06 22 10 |
| Web | https://www.photocure.com |
Photocure ASA Management Efficiency
The company has return on total asset (ROA) of (0.0309) % which means that it has lost $0.0309 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.1567) %, meaning that it generated substantial loss on money invested by shareholders. Photocure ASA's management efficiency ratios could be used to measure how well Photocure ASA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 3 records | CEO Age | ||
| Kevin Gorman | Neurocrine Biosciences | 66 | |
| Brendan OGrady | Assertio Therapeutics | N/A | |
| Sheldon Koenig | Esperion Therapeutics | 58 | |
Management Performance
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0309 |
Photocure ASA Leadership Team
Elected by the shareholders, the Photocure ASA's board of directors comprises two types of representatives: Photocure ASA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Photocure. The board's role is to monitor Photocure ASA's management team and ensure that shareholders' interests are well served. Photocure ASA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Photocure ASA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tolv Hillestad, Group Controller | ||
| Erik Dahl, Chief Officer | ||
| Patricia Kelly, VP HR | ||
| David Moskowitz, Head Relations | ||
| Daniel Schneider, President CEO | ||
| Anders Neijber, Clinical Affairs | ||
| Kari MD, Head Devel | ||
| Geoffrey Coy, VP Operations |
Photocure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Photocure ASA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.16 | |||
| Return On Asset | -0.0309 | |||
| Profit Margin | (0.20) % | |||
| Operating Margin | (0.1) % | |||
| Current Valuation | 277.44 M | |||
| Shares Outstanding | 27.11 M | |||
| Shares Owned By Insiders | 2.98 % | |||
| Shares Owned By Institutions | 48.69 % | |||
| Price To Earning | 329.14 X | |||
| Price To Book | 5.72 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Photocure Pink Sheet
Photocure ASA financial ratios help investors to determine whether Photocure Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Photocure with respect to the benefits of owning Photocure ASA security.